The 2018 Genitourinary Cancers Symposium (ASCO GU 2018) will Feature Insights for Management of Prostate, Bladder and Kidney Cancers

Truckee, CA. (UroToday.com) – The 2018 Genitourinary Cancers Symposium will take place February 8-10, 2018 in San Francisco, California. Presentations at the Symposium will discuss the latest strategies in the prevention, screening, diagnosis, and treatment of prostate, kidney, testicular, and bladder cancers. UroToday/GU OncToday will be providing exensive coverge of the conference.

Co-sponsors of the 2018 Genitourinary Cancers Symposium announced today four abstracts to be highlighted in the meeting’s official Press Program.

The following studies will be featured:

A randomized, phase III trial investigating the hormone therapy apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer, a form of prostate cancer currently with no approved therapies (Abstract 161).

An analysis of health-related quality of life and cost-effectiveness when docetaxel is added to first-line hormone therapy for prostate cancer (Abstract 162).

A study evaluating a prognostic model to predict overall survival for patients with advanced bladder cancer receiving the immunotherapy atezolizumab (Abstract 413).

A randomized, phase III trial of atezolizumab plus bevacizumab versus sunitinib for first-line treatment of advanced kidney cancer (Abstract 578).

Login